ADAMTS13 activity
| . | ADAMTS13 threshold, % . | ADAMTS13 activity . | |||
|---|---|---|---|---|---|
| Severely deficient . | Nondeficient . | ||||
| Platelets, ×109/L . | Creatinine, mg/dL . | Platelets, ×109/L . | Creatinine, mg/dL . | ||
| Raife et al35 | 15 | 13 | 1.2 | 44 | 2.7 |
| Coppo et al21,34 | 5 | 17 | 1.3 | 67 | 5.1 |
| Kremer Hovinga et al22 | 10 | 11 | 1.6 | 22 | 4.6 |
| Cataland et al29 | 10 | 12 | 1.7 | 66 | 6.7 |
| Bentley et al36 | 15 | 16 | 1.1 | 64 | 3.5 |
| . | ADAMTS13 threshold, % . | ADAMTS13 activity . | |||
|---|---|---|---|---|---|
| Severely deficient . | Nondeficient . | ||||
| Platelets, ×109/L . | Creatinine, mg/dL . | Platelets, ×109/L . | Creatinine, mg/dL . | ||
| Raife et al35 | 15 | 13 | 1.2 | 44 | 2.7 |
| Coppo et al21,34 | 5 | 17 | 1.3 | 67 | 5.1 |
| Kremer Hovinga et al22 | 10 | 11 | 1.6 | 22 | 4.6 |
| Cataland et al29 | 10 | 12 | 1.7 | 66 | 6.7 |
| Bentley et al36 | 15 | 16 | 1.1 | 64 | 3.5 |
Reported platelet count and serum creatinine at presentation from studies of TMA patients comparing the clinical features of patients with severely deficient and nondeficient ADAMTS13 activity.